Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 8Breast Neoplasms 5Stomach Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 35Nivolumab 13Cyclophosphamide 11fludarabine 9aldesleukin 9atezolizumab 7Magnetic Resonance Spectroscopy 7Carboplatin 7Specimen Handling 6Ipilimumab 6Early Intervention, Educational 6Cisplatin 6Trastuzumab 5Paclitaxel 5Methods 5Biopsy 5Bevacizumab 5durvalumab 4Vaccines 4Surveys and Questionnaires 4Radiotherapy 4Papillomavirus Vaccines 4Interleukin-2 4Docetaxel 4tisotumab vedotin 3spartalizumab 3fludarabine phosphate 3cemiplimab 3aflibercept 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × tucatinib × Gastrointestinal × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡